Cargando…
Silodosin in the treatment of benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS due to BPH. Alpha-adrenergic receptor blockers remain one of the mainstays in the treatment of male LUTS and clinical BPH. They ex...
Autores principales: | Rossi, Maxime, Roumeguère, Thierry |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990389/ https://www.ncbi.nlm.nih.gov/pubmed/21116335 http://dx.doi.org/10.2147/DDDT.S10428 |
Ejemplares similares
-
Management of benign prostatic hyperplasia with silodosin
por: Yamanishi, Tomonori, et al.
Publicado: (2009) -
Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
por: Yoshida, Masaki, et al.
Publicado: (2011) -
Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability
por: Cho, Hee Ju, et al.
Publicado: (2014) -
Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia
por: Sakata, Koichi, et al.
Publicado: (2012) -
Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial
por: Pande, Satabdi, et al.
Publicado: (2014)